Case Report: Successful treatment of triple primary cancers (lung, stomach, and intestine) using sintilimab combined with chemotherapy and targeted therapy
This case report presents a rare instance of synchronous multiple primary cancers involving lung adenocarcinoma with bone metastasis, gastric signet-ring cell carcinoma, and rectal cancer. The 64-year-old male patient was treated with a combination of sintilimab, chemotherapy, and targeted therapy....
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1614911/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849684346424786944 |
|---|---|
| author | Qi-Qing Zhang Xin-Xin Luo Hua Chen Wei Wang Yi-Fan Xie Hong-Li Qiao Hao-Jun Miao Zheng-Quan Feng |
| author_facet | Qi-Qing Zhang Xin-Xin Luo Hua Chen Wei Wang Yi-Fan Xie Hong-Li Qiao Hao-Jun Miao Zheng-Quan Feng |
| author_sort | Qi-Qing Zhang |
| collection | DOAJ |
| description | This case report presents a rare instance of synchronous multiple primary cancers involving lung adenocarcinoma with bone metastasis, gastric signet-ring cell carcinoma, and rectal cancer. The 64-year-old male patient was treated with a combination of sintilimab, chemotherapy, and targeted therapy. Following a multidisciplinary team consultation, systemic treatment with sintilimab, oxaliplatin, and capecitabine was initiated concurrently while furmonertinib targeted therapy continued. After six cycles, the lung lesions showed significant reduction, while the gastric and intestinal tumors remained stable. The patient transitioned to maintenance therapy and achieved sustained disease control without severe adverse effects. This case highlights the potential of an integrated immunotherapy and chemotherapy approach for treating multiple primary malignancies with distinct pathological origins. report also underscores the need for individualized, biomarker-driven treatment strategies and further research on optimal therapeutic combinations for synchronous multiple primary cancers. |
| format | Article |
| id | doaj-art-346f0c0ffc03492f819f9d7ead29281a |
| institution | DOAJ |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-346f0c0ffc03492f819f9d7ead29281a2025-08-20T03:23:30ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-08-011610.3389/fimmu.2025.16149111614911Case Report: Successful treatment of triple primary cancers (lung, stomach, and intestine) using sintilimab combined with chemotherapy and targeted therapyQi-Qing Zhang0Xin-Xin Luo1Hua Chen2Wei Wang3Yi-Fan Xie4Hong-Li Qiao5Hao-Jun Miao6Zheng-Quan Feng7Department of Oncology, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, ChinaCollege of Integrated Traditional Chinese and Western Medicine Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, ChinaDepartment of Oncology, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, ChinaDepartment of Pathology, Tongde Hospital of Zhejiang Province, Hangzhou, ChinaDepartment of Pathology, Tongde Hospital of Zhejiang Province, Hangzhou, ChinaDepartment of Oncology, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, ChinaDepartment of Oncology, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, ChinaDepartment of Oncology, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, ChinaThis case report presents a rare instance of synchronous multiple primary cancers involving lung adenocarcinoma with bone metastasis, gastric signet-ring cell carcinoma, and rectal cancer. The 64-year-old male patient was treated with a combination of sintilimab, chemotherapy, and targeted therapy. Following a multidisciplinary team consultation, systemic treatment with sintilimab, oxaliplatin, and capecitabine was initiated concurrently while furmonertinib targeted therapy continued. After six cycles, the lung lesions showed significant reduction, while the gastric and intestinal tumors remained stable. The patient transitioned to maintenance therapy and achieved sustained disease control without severe adverse effects. This case highlights the potential of an integrated immunotherapy and chemotherapy approach for treating multiple primary malignancies with distinct pathological origins. report also underscores the need for individualized, biomarker-driven treatment strategies and further research on optimal therapeutic combinations for synchronous multiple primary cancers.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1614911/fullchemotherapyimmunotherapymultiple primary cancerssintilimabtargeted therapy |
| spellingShingle | Qi-Qing Zhang Xin-Xin Luo Hua Chen Wei Wang Yi-Fan Xie Hong-Li Qiao Hao-Jun Miao Zheng-Quan Feng Case Report: Successful treatment of triple primary cancers (lung, stomach, and intestine) using sintilimab combined with chemotherapy and targeted therapy Frontiers in Immunology chemotherapy immunotherapy multiple primary cancers sintilimab targeted therapy |
| title | Case Report: Successful treatment of triple primary cancers (lung, stomach, and intestine) using sintilimab combined with chemotherapy and targeted therapy |
| title_full | Case Report: Successful treatment of triple primary cancers (lung, stomach, and intestine) using sintilimab combined with chemotherapy and targeted therapy |
| title_fullStr | Case Report: Successful treatment of triple primary cancers (lung, stomach, and intestine) using sintilimab combined with chemotherapy and targeted therapy |
| title_full_unstemmed | Case Report: Successful treatment of triple primary cancers (lung, stomach, and intestine) using sintilimab combined with chemotherapy and targeted therapy |
| title_short | Case Report: Successful treatment of triple primary cancers (lung, stomach, and intestine) using sintilimab combined with chemotherapy and targeted therapy |
| title_sort | case report successful treatment of triple primary cancers lung stomach and intestine using sintilimab combined with chemotherapy and targeted therapy |
| topic | chemotherapy immunotherapy multiple primary cancers sintilimab targeted therapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1614911/full |
| work_keys_str_mv | AT qiqingzhang casereportsuccessfultreatmentoftripleprimarycancerslungstomachandintestineusingsintilimabcombinedwithchemotherapyandtargetedtherapy AT xinxinluo casereportsuccessfultreatmentoftripleprimarycancerslungstomachandintestineusingsintilimabcombinedwithchemotherapyandtargetedtherapy AT huachen casereportsuccessfultreatmentoftripleprimarycancerslungstomachandintestineusingsintilimabcombinedwithchemotherapyandtargetedtherapy AT weiwang casereportsuccessfultreatmentoftripleprimarycancerslungstomachandintestineusingsintilimabcombinedwithchemotherapyandtargetedtherapy AT yifanxie casereportsuccessfultreatmentoftripleprimarycancerslungstomachandintestineusingsintilimabcombinedwithchemotherapyandtargetedtherapy AT hongliqiao casereportsuccessfultreatmentoftripleprimarycancerslungstomachandintestineusingsintilimabcombinedwithchemotherapyandtargetedtherapy AT haojunmiao casereportsuccessfultreatmentoftripleprimarycancerslungstomachandintestineusingsintilimabcombinedwithchemotherapyandtargetedtherapy AT zhengquanfeng casereportsuccessfultreatmentoftripleprimarycancerslungstomachandintestineusingsintilimabcombinedwithchemotherapyandtargetedtherapy |